Genomind® Professional PGx ExpressTM Drug Interaction Guide™

Help ensure patient safety by fine-tuning treatments with G-DIG

How will your patient metabolize a certain drug? How will that drug interact with other drugs—and with certain lifestyle factors?

Now you can better predict before you prescribe medications and treatments.

Knowing how drugs might interact is important to patient safety and efficacy. Now there’s an easy way to know how they may interact with patient genotypes as well as with other drugs: G-DIG, the Genomind Drug Interaction Guide.

An enhancement to your Genomind Professional PGx Express testing

A complimentary addition for clinicians who use Genomind Professional PGx Express, G-DIG is a patient-specific tool designed to assist clinicians in checking gene-drug AND drug-drug interactions when prescribing medications. G-DIG allows clinicians to:

  • Choose from among the most commonly prescribed psychotropic and non-psychotropic medications to see how certain drugs might interact with the patient’s individual pharmacokinetic profile (gene-drug interactions)
  • Evaluate how drugs that the patient is already taking or that are being considered may interact with each other (drug-drug interactions)
  • Assess how smoking or drinking coffee can affect the patient’s specific drug metabolism

G-DIG offers clinicians an easy, manageable way to assess a patient’s gene-drug and drug-drug interactions

Assessing gene-drug AND drug-drug interactions can be labor-intensive and yield an overwhelming amount of information. Not with G-DIG. Simply log into the Genomind Clinician Portal to access G-DIG for each of your patients who have been tested with Genomind Professional PGx.

G-dig interaction guide

Understanding Phenoconversion

The phenomenon known as phenoconversion occurs when an individual with a “Normal Metabolizer” genotype is converted into Poor Metabolizer (PM) status as a result of drugs or environmental factors. Monitoring only patient genotypes may miss about 20% of patients who actually have a PM phenotype (secondary to their drug regimen).1,2 Conversely, failing to assess a patient’s genotype may underestimate altered metabolism risk. Roughly 6% to 40% of people exist as poor metabolizers or ultra-rapid metabolizers, respectively, across populations.3-6

Search for the most common medications currently prescribed

G-DIG allows you to explore interactions among the most-prescribed drugs, including:

  • Alprazolam
  • Aripiprazole
  • Bupropion
  • Duloxetine
  • Escitalopram
  • Gabapentin
  • Methylphenidate
  • Quetiapine
  • Sertraline
  • Amlodipine
  • Atorvastatin
  • Ciprofloxacin
  • Clopidogrel
  • Losartan
  • Metoprolol
  • Omeprazole
  • Prednisone
  • Warfarin

Exclusive to G-DIG: environmental modifiers

In addition to allowing the layering of gene-drug and drug-drug interactions, G-DIG is also the first tool of its kind to incorporate the important environmental factors of tobacco smoking and coffee consumption into personalized treatment decisions.

Dig Deeper, With G-DIG

G-DIG makes it easier for you to further personalize your patient’s treatment when using Genomind Professional PGx. To learn more or to see a demonstration, speak with your Genomind representative.


1. Shah RR, Smith Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol 79, 222-240, doi:10.1111/bcp.12441 (2015).
2. Preskorn SH, et Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 74, 614-621, doi:10.4088/JCP.12m07807 (2013).
3. 1000 Genomes
4. Barter ZE, Tucker GT, Rowland-Yeo Differences in cytochrome p450-mediated pharmacokinetics between Chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52, 1085-1100, doi:10.1007/s40262-013-0089-y (2013).
5. A, L. et al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 10, 1569-1583, doi:10.1517/17425255.2014.964204 (2014).
6. Sistonen J, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17, 93-101, doi:10.1097/01.fpc.0000239974.69464.f2 (2007).

Pharmacogenetics should not only be about the interactions of medications with body but also about interactions between drugs. With psychiatric prescribing, polypharmacy is common. G-DIG enables the Genecept Assay to be an even more complete tool, addressing both gene and drug interactions. It illustrates for the prescriber and the patient the efficacious use of medications, including their potential interactions. It can help to decrease side effects and aid in adding other medications to balance side effects, therefore decreasing noncompliance and patient hospitalization.

Sharon R. Katz, MSN FPMH-APRN

} ); } ( jQuery ) );